A previous clinical trial found that tamoxifen, taken for five years, reduced the risk of developing invasive breast cancer by about 50% in post-menopausal women who were at increased risk of getting the disease.
Another trial found that five years of raloxifene reduces breast cancer risk in such women by about 38%.
Under the new plans, high risk post-menopausal women could be offered the drugs for a period of five years unless they have a history of thromboembolic disease or endometrial cancer.
More top news
As the world remembers the Holocaust, an Auschwitz survivor says he remains "fearful" following the attack on a Jewish supermarket in Paris.
Police are hunting four men who smashed their way into a jewellers in broad daylight and threatened staff with sledgehammers.
ComRes polling agency chairman says the next 100 days will be be gruelling in the most uncertain General Election that anyone can remember.